Celine Halioua On The Science and Business of Making Dogs Live Longer

What It Covers

Celine Halioua, founder of Loyal, explains her strategy to develop FDA-approved longevity drugs for dogs first, having raised over $250 million. She details milestone-based fundraising for biotech, regulatory pathways, clinical trials with 1,300 dogs, and plans to translate findings into human longevity treatments.

Key Questions Answered

• •Milestone-Based Biotech Fundraising: Deep tech companies raise capital differently than software startups. Instead of revenue metrics, biotech valuations increase as a fraction of future market value with each milestone that raises probability of FDA approval. Loyal mapped regulatory milestones (efficacy, safety, manufacturing) years in advance, understanding that investors underwrite specific FDA approvals, not just promising data.
• •Conditional Approval Pathway: Loyal secured FDA efficacy and safety approval for their first drug before full market launch, eliminating the primary biological risks that cause most drugs to fail. With manufacturing as the remaining hurdle, the company shifted from existential risk to execution risk. This transformed investor conversations from whether the drug works to when it launches, fundamentally changing valuation dynamics.
• •Dogs as Human Drug Accelerators: Developing longevity drugs in dogs first solves the human drug development paradox. Dogs age naturally with diseases like dementia and cancer, providing better translational biology than mice (9% human drug success rate). A dog lifespan study costs approximately $50 million versus billions for humans, with results in years not decades, creating viable economics for private funding.
• •Clinical Trial Scale and Design: Loyal runs the largest animal health clinical trial in history with 1,300 pet dogs across 70+ veterinary sites. The double-blind study tracks quality of life, disease development, and lifespan until death. This consumer-driven pharmaceutical model mirrors GLP-1 weight loss drugs, where pet owners request the treatment from veterinarians rather than traditional pharma marketing approaches.
• •Revenue-Funded Moonshots Strategy: Unlike most biotech companies that exit to pharma before commercialization, Loyal plans direct-to-consumer sales through veterinarians in a cash-pay system. This revenue engine (targeting five dog drug approvals by 2030) will fund expensive human longevity trials without relying on pharma acquisition, following the Tesla model of using current product revenue to fund increasingly ambitious next-generation development.